{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:13:52Z","timestamp":1788178432599,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115200","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:23:17Z","timestamp":1786227797000},"page":"115200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Making Pharmaceutical Administration Evidence Cumulative: What PBPK Teaches Us About Building Knowledge Across Products"],"prefix":"10.1016","volume":"227","author":[{"given":"Carlos Victor","family":"Montefusco-Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Lopes","family":"Ribeiro Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115200_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2026.115101","article-title":"The role of pharmaceutical formulation development in clinical trials of new medicinal products","volume":"225","author":"Owczarek","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115200_b0010","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.xphs.2023.05.002","article-title":"Current industry best practice on in-use stability and compatibility studies for biological products","volume":"112","author":"Bl\u00fcmel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115200_b0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5731\/pdajpst.2022.012806","article-title":"Best practices for microbial challenge in-use studies to evaluate the microbial growth potential of parenteral biological products: industry and regulatory considerations","volume":"78","author":"Zamiri","year":"2024","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115200_b0020","unstructured":"European Medicines Agency. Note for guidance on in-use stability testing of human medicinal products. CPMP\/QWP\/2934\/99. Effective 1 September 2001. https:\/\/www.ema.europa.eu\/en\/use-stability-testing-human-medicinal-products-scientific-guideline."},{"key":"10.1016\/j.ejpb.2026.115200_b0025","unstructured":"European Medicines Agency. Quality of medicines: questions and answers, Part 2. Section on in-use stability after opening, reconstitution, or dilution. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/quality-medicines-questions-answers-introduction\/quality-medicines-questions-answers-part-2. Accessed 20 July 2026."},{"key":"10.1016\/j.ejpb.2026.115200_b0030","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115200_b0035","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115200_b0040","unstructured":"U.S. Food and Drug Administration. Physiologically based pharmacokinetic analyses: format and content. Guidance for industry. Silver Spring, MD: FDA; 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry."},{"key":"10.1016\/j.ejpb.2026.115200_b0045","unstructured":"European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic modelling and simulation. EMA\/CHMP\/458101\/2016. Effective 1 July 201https:\/\/www.ema.europa.eu\/en\/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation-scientific-guideline."},{"key":"10.1016\/j.ejpb.2026.115200_b0050","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.xphs.2017.05.028","article-title":"Protein adsorption to in-line filters of intravenous administration sets","volume":"106","author":"Besheer","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115200_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR guiding principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci. Data"},{"key":"10.1016\/j.ejpb.2026.115200_b0060","unstructured":"U.S. Food and Drug Administration. Population pharmacokinetics. Guidance for industry. Silver Spring, MD: FDA; 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/population-pharmacokinetics."},{"key":"10.1016\/j.ejpb.2026.115200_b0065","unstructured":"International Council for Harmonisation. ICH Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. Geneva: ICH; 2019. https:\/\/database.ich.org\/sites\/default\/files\/Q12_Guideline_Step4_2019_1119.pdf."},{"key":"10.1016\/j.ejpb.2026.115200_b0070","doi-asserted-by":"crossref","unstructured":"Organisation for Economic Co-operation and Development. Users' handbook supplement to the guidance document for developing and assessing Adverse Outcome Pathways. OECD Series on Adverse Outcome Pathways No. 1. Paris: OECD Publishing; 2018. Doi:10.1787\/5jlv1m9d1g32-en.","DOI":"10.1787\/5jlv1m9d1g32-en"},{"key":"10.1016\/j.ejpb.2026.115200_b0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5731\/pdajpst.2020.011825","article-title":"Knowledge management as a pharmaceutical quality system enabler: how enhanced knowledge transfer can help close the ICH Q10 to ICH Q12 gap","volume":"75","author":"Lipa","year":"2021","journal-title":"PDA J. Pharm. Sci. Technol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:17:05Z","timestamp":1788175025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S0939641126002213"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115200","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Making Pharmaceutical Administration Evidence Cumulative: What PBPK Teaches Us About Building Knowledge Across Products","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115200"}}